Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global West Nile Virus Infections Drugs and Companies Pipeline Review H2 2016

Thursday, October 20, 2016 22:47
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘West Nile Virus Infections – Pipeline Review, H2 2016’, provides an overview of the West Nile Virus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for West Nile Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693302-west-nile-virus-infections-pipeline-review-h2-2016

Scope

- The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections
- The report reviews pipeline therapeutics for West Nile Virus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved West Nile Virus Infections therapeutics and enlists all their major and minor projects
- The report assesses West Nile Virus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for West Nile Virus Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Complete report details @ https://www.wiseguyreports.com/reports/693302-west-nile-virus-infections-pipeline-review-h2-2016

 

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Report Coverage 6
West Nile Virus Infections Overview 7
Therapeutics Development 8
Pipeline Products for West Nile Virus Infections – Overview 8
Pipeline Products for West Nile Virus Infections – Comparative Analysis 9
West Nile Virus Infections – Therapeutics under Development by Companies 10
West Nile Virus Infections – Therapeutics under Investigation by Universities/Institutes 11
West Nile Virus Infections – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
West Nile Virus Infections – Products under Development by Companies 14
West Nile Virus Infections – Products under Investigation by Universities/Institutes 15
West Nile Virus Infections – Companies Involved in Therapeutics Development 16
CEL-SCI Corporation 16
Hemispherx Biopharma, Inc. 17
Kineta, Inc. 18
Nanotherapeutics, Inc. 19
Plex Pharmaceuticals, Inc. 20
West Nile Virus Infections – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Alferon LDO – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
BG-323 – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CEL-1000 – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
FDX-000 – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
HydroVax-001 – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
interferon alfa-n3 – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
KIN-1148 – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
KIN-1400 – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Monoclonal Antibody for West Nile Virus Infections – Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
rintatolimod – Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
RL-15A – Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, Zika and West Nile Virus Infection – Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules for Viral Infections – Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections – Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections – Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Synthetic Peptide for Dengue Virus and West Nile Virus Infections – Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Tatbeclin-1 – Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
West Nile virus vaccine – Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
West Nile virus vaccine – Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
West Nile Virus Infections – Dormant Projects 63
West Nile Virus Infections – Product Development Milestones 66
Featured News & Press Releases 66
Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials 66
May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro 67
Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena 67
Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection 68
Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

Get It Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693302

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.